The m7G regulators, such as METTL1, WDR4, AGO2, and NUDT1, can be considered cancer biomarkers, and m7G modification frequently correlates to tumorous prognosis in certain cancers, including intrahepatic cholangiocarcinoma [15], bladder cancer [16], uterine corpus endometrial carcinoma [17], gastric cancer [18], and hepatocellular carcinoma [19]. This evidence concerns the gene METTL1 and cancer.